Objective: To study the effect of GcMAF on the general condition of patient, changes in motor activity and improvement of liver parameters after treatment.
Background: Gc protein-derived macrophage-activating factor (GcMAF) is a naturally occurring glycoprotein in the human body that activates phagocytic macrophages. GcMAF exists in cells as an inactive glycoprotein, which is activated when the body needs protection from pathogens or cancer cells. Administration external GcMAF in active form can provide a pathway for macrophage activation. GcMAF also generates superoxide free radicals and has an antiangiogenic effect. GcMAF is suitable in treatment of cancer, autism, multiple sclerosis, Lyme disease, chronic fatigue syndrome, liver cirrhosis and various infectious diseases. Possible uses include Parkinson’s, Alzheimer’s diseases, dementia, etc. There are several studies on patients who took this glycoprotein and they showed clear improvement after treatment.
Method: A 45-y.o. patient from Uzbekistan. Complaints: imbalance, unsteady gait, tremors of arms, legs, head, even at rest. Speech impairment. General weakness, abdominal pain and nausea, loss of appetite and vomiting, tinnitus. Since 2015, he has been diagnosed with multiple sclerosis. The course of the disease is wave-like. After the last taking of Levocarnitine (Almiba) and Carbamazepine, tremor increased throughout the body. He could not walk. About 2 years ago, frequent vomiting began. At the end of 2018, examination by a neurologist and therapist: horizontal nystagmus, paraparesis of the arms and legs, impaired deep sensitivity, diffuse muscle hypotension, intentional tremor of the limbs, trunk and head. Gait ataxic. Chanted speech. Liver cirrhosis due to Hepatitis B. Complications: portal hypertension. Splenomegaly. In early 2019, the first time took GcMAF 0.25 ml twice a week. He took it for a month regularly. Then intermittently.
Results: A 3 months after the start of treatment, he felt improvement in general condition: movements became controlled, tremor of limbs and head decreased, speech became a little understandable, sleep was normalized, vomiting and abdominal pain gradually subsided. Comparing liver fibroscans before treatment and after GcMAF, there is a significant improvement. Before treatment-15.3 kPa, after-7.8 kPa.
Conclusion: GcMAF is effective in treating MS and cirrhosis. It can be used as the main or additional method of treatment.
To cite this abstract in AMA style:DrD. Mirzaeva. Using of GcMAF in patient from Uzbekistan with MS and a concomitant liver cirrhosis due to Hepatitis B [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/using-of-gcmaf-in-patient-from-uzbekistan-with-ms-and-a-concomitant-liver-cirrhosis-due-to-hepatitis-b/. Accessed November 28, 2023.
« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/using-of-gcmaf-in-patient-from-uzbekistan-with-ms-and-a-concomitant-liver-cirrhosis-due-to-hepatitis-b/